SV

Street Verdict

Analyst Scorecard

A record of what Nuvama Analysis said publicly, with the source. Not advice.

“Maintains a 'hold' rating on NATCO Pharma, slashing its target price to ₹1,100 from ₹1,440. This revision follows an "all-round miss" in Q3 performance, with prolonged weakness expected in India and Agrochem businesses, alongside higher price erosion in gRevlimid sales from H2FY26 onwards. The revised target suggests a potential upside of 25.5% from Friday's low.”

Nuvama Analysis’s track record (trackable calls only): 161 graded calls · 95% CI 35–50%

NATCO Pharma LtdNeutralCalled 14 Feb 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Nuvama Analysis’s full track record